BLCM - Bellicum Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Bellicum Pharmaceuticals, Inc.

2130 West Holcombe Boulevard
Suite 800
Houston, TX 77030
United States
832-384-1100
http://www.bellicum.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees173

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard A. FairPres, CEO & Director848.92kN/A1969
Mr. Shane M. WardGen. Counsel & Corp. Sec.442.51kN/A1975
Mr. Atabak MokariChief Financial OfficerN/AN/A1977
Ms. Rosemary Y. WilliamsInterim Principal Accounting Officer, VP of Fin. & ControllerN/AN/AN/A
Dr. Alan K. SmithExec. VP of Technical OperationsN/AN/A1958
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Corporate Governance

Bellicum Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.